Question

• Consider the following scenario: Your patient has suffered from schizophrenia for two decades and has received classic dopaminergic treatments since the onset of illness. The latest research supporting use of the glutamatergic model has not been tried on your patient, and there is an opportunity for your patient to enter clinical trials utilizing glutamate-based treatments. Your patient suffers significant executive function impairment and memory impairment. Do you recommend participation in the clinical trial? Why or why not?

Answer 1

Dopamine and glutamate having interaction in the brain with interneural and intraneural action. Interactions by reciprocal release regulations of neurotransmitters by interactive control of depolarization and gene expression. there will be dysfunctional interaction between dopamine and glutamine system results with numerous neuropsychiatric disorders. dopamine is a neurotransmitter it regulates the brain function with body chemicals messages facilitate communication between nerve cells in the nervous system. glutamate also neurotransmitter having action. when there is a high neurotransmitter reaction in the brain it causes hallucinations and delusions during psychosis illness.